Indivior Pharmaceuticals, Inc. INDV
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders.
Headquartered in the U.S. in Richmond, Virginia, Indivior and its portfolio of products is available primarily in the U.S. with additional products available in Canada, Australia, France, and Germany.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2014 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.24B | $1.19B | $1.09B | $901.0M | — | — | — |
| Cost of revenue | $246.0M | $231.0M | $174.0M | $151.0M | — | — | — |
| Gross profit | $994.0M | $957.0M | $919.0M | $749.0M | — | — | — |
| SG&A | $634.0M | $612.0M | $565.0M | $469.0M | — | — | — |
| Total operating expenses | — | $919.0M | $1.07B | $831.0M | — | — | — |
| Operating income | $262.0M | $38.0M | -$152.0M | -$81.0M | $213.0M | — | — |
| Interest expense | $45.0M | $41.0M | $35.0M | $27.0M | — | — | — |
| Pre-tax income | $239.0M | $20.0M | -$145.0M | -$89.0M | — | — | — |
| Income tax | $29.0M | $13.0M | $19.0M | $44.0M | — | — | — |
| Net income | $210.0M | $7.0M | -$126.0M | -$44.0M | $205.0M | — | — |
| EPS, basic | 1.68 | 0.05 | -0.92 | -0.32 | — | — | — |
| EPS, diluted | 1.64 | 0.05 | -0.92 | -0.32 | — | — | — |
| Shares, diluted (wtd. avg.) | $128.0M | $133.0M | $137.0M | $139.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2014 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $195.0M | $319.0M | $316.0M | $774.0M | $1.10B | — | — |
| Short-term investments | $0 | $1.0M | $94.0M | — | — | — | — |
| Receivables | $253.0M | $254.0M | $254.0M | — | — | — | — |
| Inventory | $153.0M | $167.0M | $126.0M | — | — | — | — |
| Total current assets | $652.0M | $827.0M | $1.26B | — | — | — | — |
| Property, plant and equipment | $144.0M | $100.0M | $84.0M | — | — | — | — |
| Goodwill | $2.0M | $2.0M | $5.0M | — | — | — | — |
| Total assets | $1.20B | $1.32B | $1.76B | $1.77B | $1.83B | — | — |
| Accounts payable | $48.0M | $63.0M | $195.0M | — | — | — | — |
| Short-term debt | $29.0M | $18.0M | $3.0M | — | — | — | — |
| Total current liabilities | $914.0M | $924.0M | $1.28B | — | — | — | — |
| Long-term debt | $290.0M | $315.0M | $237.0M | — | — | — | — |
| Total liabilities | $1.30B | $1.65B | $1.94B | — | — | — | — |
| Retained earnings | -$243.0M | -$443.0M | -$288.0M | — | — | — | -$1.29B |
| Total equity | -$98.0M | -$337.0M | -$184.0M | -$15.0M | $121.0M | $82.0M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2014 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.0M | $36.0M | -$300.0M | -$4.0M | — | — | — |
| Depreciation and amortisation | $10.0M | $16.0M | $15.0M | $16.0M | — | — | — |
| Stock-based compensation | $26.0M | $24.0M | $21.0M | $16.0M | — | — | — |
| Capital expenditure | $66.0M | $29.0M | $8.0M | $5.0M | — | — | — |
| Investing cash flow | -$66.0M | $69.0M | -$95.0M | -$222.0M | — | — | — |
| Financing cash flow | -$30.0M | -$102.0M | -$64.0M | -$101.0M | — | — | — |
| Buybacks | $11.0M | $173.0M | $33.0M | $90.0M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-012237.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |